Clinical Trial Update: Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 [Phase 1]

View source ↗

Summary

This document reports an extension-phase study of UC-961 (cirmtuzumab) in patients with chronic lymphocytic leukemia; results have been posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• UC-961 (Cirmtuzumab) (cirmtuzumab)

Snippet

Sponsor: University of California, San Diego | Conditions: Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED | Results posted: 2025-12-15